Summary A specific two-site ELISA for human epidermal growth factor (hEGF) has been used to measure urinary hEGF/creatinine ratios in 30 normal subjects, 30 hospital in-patients with breast cancer and 30 hospital in-patients with colonic or rectal cancer. There was no significant difference between patients with breast cancer and controls. Although a statistically significant difference between patients with colorectal cancer and controls was observed, the biological significance of this observation is doubtful. No clear effect of the presence of breast or colorectal carcinoma on the urinary excretion of hEGF has been observed.
Human epidermal growth factor (hEGF, urogastrone) is a heat-and acid-stable polypeptide of molecular weight 6000, originally isolated from human urine and found to be identical to the gastric anti-secretory hormone, B urogastrone (Gregory et al., 1977) . It is involved in the regulation of proliferation of numerous cell types. Its receptor is the product of the C-erb-B proto-oncogene, suggesting a possible role for hEGF in malignant transformation (Downward et al., 1984) . Three previous studies have demonstrated elevated levels of urinary hEGF in patients with malignant disease, suggesting that it may have a clinical application as a tumour marker (Uchihashi et al., 1983; Kurobe et al., 1985; Strom-'berg et at., 1989 The control subjects in this study were not matched for sex or age since, in our initial studies, no obvious trend was seen for differences in urinary hEGF with sex or with increasing age. Although marked age differences in urinary hEGF are reported, these are most distinct up to puberty, and the differences thereafter are much smaller (Matilla et al., 1985) . The characteristics of the three groups are shown in Table I .
Assay procedures Urinary hEGF was measured by a specific 2-site ELISA using a mouse monoclonal anti-hEGF, 3D3 (hybridoma generously donated by Dr K. Nishikawa, Uchinda, Japan) (Yoshitake & Nishikawa, 1985) , as the capturing antibody, and a sheep polyclonal anti-hEGF as the secondary antibody. A recombinant hEGF (Searle Research and Development, UK) was employed as the standard. All samples were assayed in duplicate and at several dilutions. The assay system is highly specific for hEGF. Mouse salivary gland EGF and human TGF, when tested up to a concentration of 12 mg ml-' failed to be detected in the ELISA. The assay detects hEGF in the urine to a level of 50 pg ml-'. Figure 1 -demonstrates typical results with recombinant and native urinary hEGF, demonstrating parallel dilution curves for both. Urinary creatinine levels were measured in the Department of Chemical Pathology, Southampton General Hospital, on a Beckmann-Astra auto analyser using the kinetic method of Jaffe (Lustgarten & Wenk, 1972) . Statistical analysis was performed using the Students t-test.
Results
The results for hEGF/creatinine are shown in Table II and Figure 2 . No sex difference in hEGF/creatinine was apparent and no clear relationship with age was found. The difference in hEGF/creatinine between normal subjects and patients with colorectal carcinoma achieves statistical significance at the 95% level. No significant difference was observed between normal subjects and patients with breast carcinomas. Despite the statistically significant difference, Figure 2 illustrates a wide variability within each group, and considerable overlap.
Discussion
In this study, a statistically significant difference was observed between urinary hEGF levels of patients with colorectal carcinomas, compared with normal subjects. The biological significance of this observation is, however, doubtful, in view of the large overlap demonstrated in Figure 2 . It appears to have no clinical application as a marker of colorectal or breast carcinoma in this study. Although the control group in this study was not age and sex matched, no obvious differences in urinary hEGF between sexes, or at different ages, were observed. Sex and age related differences in urinary hEGF have been reported (Matilla, 1986) , but their magnitude in the 20-60 year age group is small and therefore, the lack of matched controls is unlikely to have affected these results significantly.
In contrast to the findings in this study, Uchihashi et al. (1983) measured urinary immunoreactive hEGF/creatinine levels in a series of patients with various malignancies. They demonstrated supranormal levels in patients with carcinomas of the lung, maxilla, oesophagus, stomach, thyroid, breast and cervix, and in lymphoma, leukaemia and myeloma. Kurobe et al. (1985) demonstrated elevated levels of urinary hEGF/creatinine in patients with gastric pathology. Conversely, Cartlidge & Elder (1988) demonstrated reduced urinary hEGF/creatinine levels in patients with gastric carcinomas, compared with age and sex matched controls.
A report of a single patient with an astrocytoma describes a high molecular weight form of hEGF in the urine, present at high level, which could not be detected following complete surgical excision of the tumour (Stromberg et al., 1987) . In a more recent study, Matilla et al. (1988) studied 97 adults with carcinomas of the bladder, kidney, stomach, colon, rectum, breast, cervix and endometrium. Significantly elevated urinary hEGF was found only in females with endometrial carcinoma, and the levels did not return to normal after surgery. The authors suggested that this elevation may be mediated by high oestrogen levels.
In the light of current knowledge, the lack of correlation between urinary hEGF and malignant disease is not surprising. Evidence for the excessive production of hEGF by tumours is poor, and although immunoreactive hEGF can be found in tumours on histological staining, it has only rarely been found in tumour extracts (Mori et al., 1987) . Furthermore, most urinary hEGF is derived from the kidneys (Rall et al., 1985; Gubits et al., 1986) and, even if tumour-derived hEGF were excreted into the urine, the amounts would be unlikely to produce a significant increase. Where elevated levels of hEGF have been found, this may represent an indirect effect of a tumour product on renal hEGF production. It has been shown that athymic rats bearing a human tumour xenograft, A673, have increased urinary levels of rat EGF, with no human equivalent present (Hudgins et al., 1988) . This study, therefore, has failed to demonstrate any effect of breast or colon carcinomas on the urinary excretion of hEGF compared with normal subjects.
